 DURHAM, N.C.--BUSINESS WIRE--- DTIL ARCUS--Precision BioSciences, Inc. Nasdaq: DTIL, a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will present preclinical data for its chronic hepatitis B virus HBV program at the HEP DART 2021 conference taking place in Cabo San Lucas, Mexico, December 5 9, 2021. Presentation Details: Abstract Number and Title: Abstract 03. Targeting Hepatitis B cccD 